[go: up one dir, main page]

AU2003302626A1 - 1, 2, 5-thiadiazolidin-3-one 1, 1 dioxide derivatives as inhibitors of protein tyrosine phosphatase ptp1b - Google Patents

1, 2, 5-thiadiazolidin-3-one 1, 1 dioxide derivatives as inhibitors of protein tyrosine phosphatase ptp1b

Info

Publication number
AU2003302626A1
AU2003302626A1 AU2003302626A AU2003302626A AU2003302626A1 AU 2003302626 A1 AU2003302626 A1 AU 2003302626A1 AU 2003302626 A AU2003302626 A AU 2003302626A AU 2003302626 A AU2003302626 A AU 2003302626A AU 2003302626 A1 AU2003302626 A1 AU 2003302626A1
Authority
AU
Australia
Prior art keywords
thiadiazolidin
inhibitors
protein tyrosine
tyrosine phosphatase
dioxide derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003302626A
Inventor
Peter Wedderburn Kenny
Andrew David Morley
Daniel John Russell
Dorin Toader
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of AU2003302626A1 publication Critical patent/AU2003302626A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/10—1,2,5-Thiadiazoles; Hydrogenated 1,2,5-thiadiazoles

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2003302626A 2002-11-29 2003-11-26 1, 2, 5-thiadiazolidin-3-one 1, 1 dioxide derivatives as inhibitors of protein tyrosine phosphatase ptp1b Abandoned AU2003302626A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0227813A GB0227813D0 (en) 2002-11-29 2002-11-29 Chemical compounds
GB0227813.3 2002-11-29
PCT/GB2003/005120 WO2004050646A1 (en) 2002-11-29 2003-11-26 1, 2, 5-thiadiazolidin-3-one 1, 1 dioxide derivatives as inhibitors of protein tyrosine phosphatase ptp1b

Publications (1)

Publication Number Publication Date
AU2003302626A1 true AU2003302626A1 (en) 2004-06-23

Family

ID=9948724

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003302626A Abandoned AU2003302626A1 (en) 2002-11-29 2003-11-26 1, 2, 5-thiadiazolidin-3-one 1, 1 dioxide derivatives as inhibitors of protein tyrosine phosphatase ptp1b

Country Status (3)

Country Link
AU (1) AU2003302626A1 (en)
GB (1) GB0227813D0 (en)
WO (1) WO2004050646A1 (en)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60327811D1 (en) * 2002-12-30 2009-07-09 Vertex Pharma SULFHYDANTOINES AS PHOSPHATISOSTERES FOR USE AS PHOSPHATASE INHIBITORS IN THE TREATMENT OF CANCER AND AUTOIMMUNE DISEASES
WO2005035551A2 (en) 2003-10-08 2005-04-21 Incyte Corporation Inhibitors of proteins that bind phosphorylated molecules
WO2006028970A1 (en) 2004-09-02 2006-03-16 Cengent Therapeutics, Inc. Derivatives of thiazole and thiadiazole inhibitors of tyrosine phosphatases
EP1963294B1 (en) * 2005-12-08 2012-10-10 Novartis AG 1,2,5-thiazolidine derivatives useful for treating conditions mediated by protein tyrosine phosphatases (ptpase)
UA94921C2 (en) * 2005-12-08 2011-06-25 Новартис Аг 1-orthofluorophenyl substituted 1, 2, 5-thiazolidinedione derivatives as ptp-as inhibitors
UA94724C2 (en) * 2005-12-08 2011-06-10 Новартис Аг Thiadiazolidinone derivatives as antidiabetic agents
KR20080074966A (en) * 2005-12-08 2008-08-13 노파르티스 아게 1,1,3-trioxo-1,2,5-thiadiazolidine and its use as PET-ASE inhibitor
US8084448B2 (en) 2006-03-31 2011-12-27 Novartis Ag Organic compounds
AU2007283113A1 (en) 2006-08-08 2008-02-14 Sanofi-Aventis Arylaminoaryl-alkyl-substituted imidazolidine-2,4-diones, processes for preparing them, medicaments comprising these compounds, and their use
WO2008067527A1 (en) * 2006-12-01 2008-06-05 Novartis Ag Inhibitors of protein tyrosine phosphatase for the treatment of muscle atrophy and related disorders
AR066820A1 (en) * 2007-06-04 2009-09-16 Novartis Ag TIADIAZOLIDIN-3 ONA COMPOUNDS
EP2025674A1 (en) 2007-08-15 2009-02-18 sanofi-aventis Substituted tetra hydro naphthalines, method for their manufacture and their use as drugs
MX2011004258A (en) 2008-10-22 2011-06-01 Merck Sharp & Dohme Novel cyclic benzimidazole derivatives useful anti-diabetic agents.
CA2741672A1 (en) 2008-10-31 2010-05-06 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
WO2010068601A1 (en) 2008-12-08 2010-06-17 Sanofi-Aventis A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
BR112012003973A2 (en) 2009-08-26 2015-09-08 Sanofi Sa crystalline heteroaromatic fluoroglycoside hydrates, pharmaceuticals comprising these compounds and their use
CA2786314A1 (en) 2010-02-25 2011-09-01 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
SG192941A1 (en) 2011-02-25 2013-09-30 Merck Sharp & Dohme Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents
US8895547B2 (en) 2011-03-08 2014-11-25 Sanofi Substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof
WO2012120050A1 (en) 2011-03-08 2012-09-13 Sanofi Novel substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof
US8710050B2 (en) 2011-03-08 2014-04-29 Sanofi Di and tri- substituted oxathiazine derivatives, method for the production, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
WO2012120053A1 (en) 2011-03-08 2012-09-13 Sanofi Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
WO2012120056A1 (en) 2011-03-08 2012-09-13 Sanofi Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
EP2683701B1 (en) 2011-03-08 2014-12-24 Sanofi Oxathiazine derivatives substituted with benzyl or heteromethylene groups, method for their preparation, their usage as medicament, medicament containing same and its use
WO2012120052A1 (en) 2011-03-08 2012-09-13 Sanofi Oxathiazine derivatives substituted with carbocycles or heterocycles, method for producing same, drugs containing said compounds, and use thereof
EP2683705B1 (en) 2011-03-08 2015-04-22 Sanofi Di- and tri-substituted oxathiazine derivates, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
US8809325B2 (en) 2011-03-08 2014-08-19 Sanofi Benzyl-oxathiazine derivatives substituted with adamantane and noradamantane, medicaments containing said compounds and use thereof
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
JP6371765B2 (en) 2012-07-31 2018-08-08 ザ・ボード・オブ・リージェンツ・オブ・ザ・ユニバーシティ・オブ・テキサス・システムＴｈｅ Ｂｏａｒｄ Ｏｆ Ｒｅｇｅｎｔｓ Ｏｆ Ｔｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｔｅｘａｓ Ｓｙｓｔｅｍ Pharmaceutical composition for the treatment of diabetes
KR20150036245A (en) 2012-08-02 2015-04-07 머크 샤프 앤드 돔 코포레이션 Antidiabetic tricyclic compounds
MX2015010935A (en) 2013-02-22 2015-10-29 Merck Sharp & Dohme Antidiabetic bicyclic compounds.
EP2970119B1 (en) 2013-03-14 2021-11-03 Merck Sharp & Dohme Corp. Novel indole derivatives useful as anti-diabetic agents
JP6318467B2 (en) * 2013-04-18 2018-05-09 Jsr株式会社 Liquid crystal aligning agent, liquid crystal aligning film, liquid crystal display element, retardation film, retardation film production method and polymer
WO2015051496A1 (en) 2013-10-08 2015-04-16 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
EP3551176A4 (en) 2016-12-06 2020-06-24 Merck Sharp & Dohme Corp. ANTIDIABETIC HETEROCYCLIC COMPOUNDS
EP3558298A4 (en) 2016-12-20 2020-08-05 Merck Sharp & Dohme Corp. ANTIDIABETIC SPIROCHROMAN COMPOUNDS

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2381397A (en) * 1996-04-19 1997-11-12 Novo Nordisk A/S Modulators of molecules with phosphotyrosine recognition units
AU2825899A (en) * 1998-03-12 1999-09-27 Novo Nordisk A/S Modulators of protein tyrosine phosphatases (ptpases)
DE10038709A1 (en) * 2000-08-09 2002-02-28 Aventis Pharma Gmbh Substituted and unsubstituted benzooxathiazoles and compounds derived from them
EP2341049A1 (en) * 2002-04-03 2011-07-06 Novartis AG 5-substituted 1,1-dioxo-[1,2,5]thiazolidine-3-one derivatives as PTPASE 1B inhibitors

Also Published As

Publication number Publication date
GB0227813D0 (en) 2003-01-08
WO2004050646A1 (en) 2004-06-17

Similar Documents

Publication Publication Date Title
AU2003302626A1 (en) 1, 2, 5-thiadiazolidin-3-one 1, 1 dioxide derivatives as inhibitors of protein tyrosine phosphatase ptp1b
AU2002305205A1 (en) 9-deazaguanine derivatives as inhibitors of gsk-3
AUPR392301A0 (en) Protein phosphatase inhibitors
WO2003035617A3 (en) Derivatives of uk-2a
MA27230A1 (en) AMINOINDAZOLES DERIVATIVES AS PROTEIN KINASE INHIBITORS
AU2001268154A1 (en) Indolinone derivatives as protein kinase/phosphatase inhibitors
AU2002316137A1 (en) Method of determining protein interaction inhibitors
AU2002362197A1 (en) Method of stabilizing protein
HUP0500111A3 (en) Indolinone derivatives useful as protein kinase inhibitors
WO2003047520A3 (en) SUBSTITUTED AMINO METHYL FACTOR Xa INHIBITORS
AU2001297856A1 (en) Method for determining homeostasis of the skin
AU2003282804A1 (en) 3-(3,5-disubstituted-4-hydroxyphenyl)propionamide derivatives as cathepsin b inhibitors
AU2003249713A1 (en) 3,4-dihydroisoquinolin-1-one derivatives as inducers of apoptosis
AU2001293538A1 (en) Novel protein tyrosine phosphatase inhibitor
AU2002241211A1 (en) Imidazo-triazine derivatives as pde 5 inhibitors
AU2002359026A1 (en) Compositon of dentifrice
WO2003072537A3 (en) Selective protein tyrosine phosphatatase inhibitors
AUPS251502A0 (en) Protein kinase inhibitors
AU2003268664A1 (en) Stabilized protein compositions
DK1487802T3 (en) 2,3-diaryl-pyrazolidine derivatives as neurotensin-degrading enzyme inhibitors
AU2002305868A1 (en) Inhibitors of reggamma
AU2001284736A1 (en) Haplotypes of the pla2g1b gene
AU2003200836A1 (en) Method for the preparation of matairesinol
AU2002312592A1 (en) Protein tyrosine phosphatase 2 gene disruptions, compositions and methods related thereto
AU2002338757A1 (en) Method for finding novel active ingredients having androgen-type properties

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase